Profile of olaparib in the treatment of advanced ovarian cancer

about

Profile of olaparib in the treatment of advanced ovarian cancer

Item

http://www.wikidata.org/entity/Q26749284

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Profile of olaparib in the treatment of advanced ovarian cancer

@ast

Profile of olaparib in the treatment of advanced ovarian cancer

@en

Profile of olaparib in the treatment of advanced ovarian cancer

@nl

type

Item

label

Profile of olaparib in the treatment of advanced ovarian cancer

@ast

Profile of olaparib in the treatment of advanced ovarian cancer

@en

Profile of olaparib in the treatment of advanced ovarian cancer

@nl

prefLabel

Profile of olaparib in the treatment of advanced ovarian cancer

@ast

Profile of olaparib in the treatment of advanced ovarian cancer

@en

Profile of olaparib in the treatment of advanced ovarian cancer

@nl

P1476

Profile of olaparib in the treatment of advanced ovarian cancer

@en

P2093

Dana M Chase

http://www.w3.org/2001/XMLSchema#string

Kristin Shields

http://www.w3.org/2001/XMLSchema#string

Shreya Patel

http://www.w3.org/2001/XMLSchema#string

P2860

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

PARP inhibitors in ovarian cancer: current status and future promise.

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.

P304

125-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/IJWH.S55906

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27186080

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

obstetrics and gynaecology

P932

4847603

http://www.w3.org/2001/XMLSchema#string